Dormant DTCs downregulate MHC class I, which is essential for CD8+ T cell recognition [101]; in addition, their microenvironment may suppress the immune system by protecting cancer cells from oxidative stress or through the expression of checkpoint ligands such as PD-L1 and secretion of immunosuppressive cytokines such as IL-6 [102,103]. Here, IL6 is linked to cancer.